This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy  • Adverse Effects  • Endocrine Diseases  • Diabetes Mellitus  • Gastroenterology  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Bridget M. Kuehn

JAMA. 2008;300(12):1403.

	Since this article does not have an abstract, we have provided the first 117 words of the full text and any section headings.

The Food and Drug Administration (FDA) has received several reports of severe pancreatitis and death among patients taking exenatide, a drug approved in 2005 for the treatment of type 2 diabetes (http://www.fda.gov/medwatch/safety/2007/safety07.htm#Byetta). The FDA had previously warned physicians to carefully monitor for signs of pancreatitis in patients taking this drug.

Since the FDA first notified physicians of a potential association between exenatide and pancreatitis in October 2007, the agency has received 6 reports of patients developing hemorrhagic or necrotizing pancreatitis while taking the drug. All of the patients were hospitalized as a result; 2 died and 4 were recovering, according to the report. The drug was discontinued in all of the patients.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?